Default: Gynecologic Oncology

ISSN: 0090-8258

Journal Home

Journal Guideline

Gynecologic Oncology Q1 Unclaimed

Academic Press Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Gynecologic Oncology is a journal indexed in SJR in Obstetrics and Gynecology and Oncology with an H index of 162. It has an SJR impact factor of 2,105 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,105.

Gynecologic Oncology focuses its scope in these topics and keywords: cancer, ovarian, cervical, gynecologic, recurrent, cell, brca, patients, prognostic, combination, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Gynecologic Oncology

2,105

SJR Impact factor

162

H Index

480

Total Docs (Last Year)

1150

Total Docs (3 years)

15477

Total Refs

5359

Total Cites (3 years)

1087

Citable Docs (3 years)

4,41

Cites/Doc (2 years)

32,24

Ref/Doc

Aims and Scope


cancer, ovarian, cervical, gynecologic, recurrent, cell, brca, patients, prognostic, combination, poor, early, trial, serous, surgery, uterine, adenocarcinoma, comparison, carcinomas, endometrial, treatment,



Best articles by citations

Apoptosis May Be an Early Event of Progestin Therapy for Endometrial Hyperplasia

View more

Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer

View more

Survival disparities in vulvar cancer patients in Commission on Cancer®-accredited facilities

View more

Persistent HPV infection after conization in patients with negative margins

View more

Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus

View more

Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy

View more

A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3)

View more

Erratum to "Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival" [Gynecol. Oncol. 155 (2019) 483-488]

View more

The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population

View more

Renal metastases of malignant gestational trophoblastic disease: The use of intravenous urography in staging

View more

High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer

View more

Erratum to "First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up"

View more
SHOW MORE ARTICLES

SGO presidential address February 3, 2003

View more

Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis

View more

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival

View more

Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer

View more

An integrated molecular profile of endometrioid ovarian cancer

View more

Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue

View more

Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction

View more

Prospective Trial of Aggressive Postoperative Bowel Stimulation Following Radical Hysterectomy

View more

The curative effect of a second curettage in persistent trophoblastic disease: A retrospective cohort survey

View more

Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma

View more

Expression of cyclooxygenase-2 (COX-2) in non-neoplastic and neoplastic vulvar epithelial lesions

View more

Primary primitive neuroectodermal tumor of the uterus: a report of two cases and review of the literature

View more

Comments

No comments ... Be the first to comment!

FAQS